EWING, N.J., Nov. 18, 2016 /PRNewswire/ -- Essential Pharmaceuticals, LLC Chief Science Officer, Dr. Adam Elhofy, has published new data on Cell-Ess® universal titer boost and optimizer in BioProcess International. The article, titled "Providing Lipids Boosts Protein Productivity: Testing a Feed Supplement with Multiple Cell Clones and Media Formulations," can be viewed in its entirety on the BioProcess International website. In addition to presenting data using Cell-Ess across various media schemes, the article discusses important considerations to be made when designing a study to evaluate media. The data presented in the publication complements a peer-reviewed study of Cell-Ess that was published earlier this year.
Cell-Ess is a universal titer boost and optimizer that can be added to an already optimized media to increase total yield and productivity per cell without impacting metabolic profile, glycosylation pattern or downstream processing. In a 5-minute video, Dr. Elhofy and Essential Pharmaceuticals CEO Allan Weber discuss what makes Cell-Ess so unique and how it's revolutionizing media optimization.
"The data published in BioProcess International demonstrate that Cell-Ess consistently increases protein productivity regardless of the media and feed scheme utilized," says Dr. Elhofy. "In addition, the study was performed with different CHO clones and at different locations, demonstrating the robustness of Cell-Ess as a titer boost in many different systems."
"At Essential Pharmaceuticals, we pride ourselves in providing solutions to meet bioproduction needs," says Allan Weber, CEO of Essential. "Process development scientists and manufacturers are able to improve their processes by simply adding Cell-Ess to their current system. The new data published in BioProcess International Magazine highlights the flexibility of Cell-Ess and provides guidance to scientists as they continue improving their processes."
About Essential Pharmaceuticals
Essential Pharmaceuticals provides surgeons, medical researchers, and manufacturers new tools to bring performance, convenience, and control to enhance the advancement of basic research and drug discovery. Established in 2006, Essential Pharmaceuticals supports the preservation and growth of human systems through expanding its product development to further medical treatments for mankind.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-bioproduction-data-on-cell-ess-universal-titer-boost-is-published-by-essential-pharmaceuticals-300365730.html
SOURCE Essential Pharmaceuticals, LLC